Literature DB >> 6708929

Reserpine binding to bovine chromaffin granule membranes. Characterization and comparison with dihydrotetrabenazine binding.

D Scherman, J P Henry.   

Abstract

[3H]Reserpine bound reversibly in vitro to chromaffin granule membranes. Binding was temperature-dependent and slow, and had biphasic kinetics. The addition of ATP accelerated the kinetics, which became monophasic and comparable to those of [3H] dihydrotetrabenazine, without affecting the binding equilibrium constants. The ATP effect was related to H+ -electrochemical gradient generation by the granule membrane H+ pump. Binding of reserpine to chromaffin granule membranes occurred on two classes of sites: R1, Bmax = 7 pmoles/mg of protein and KD = 0.7 nM, and R2, Bmax = 60 pmoles/mg of protein and KD = 25 nM. Sites R2 were considered to be equivalent to [3H] dihydrotetrabenazine binding sites, as the densities of the R2 and the [3H] dihydrotetrabenazine binding sites were similar and because tetrabenazine displaced reserpine from R2 sites. Sites R1 were tetrabenazine-resistant; they were involved in monoamine uptake, since their KD values were similar to the KI values of reserpine for noradrenaline uptake. Sites R1 were less abundant than sites R2 on chromaffin granule membranes, but they were present at the same concentration in intact chromaffin granules. We propose that the monoamine carrier exists in two forms: (a) an active form bearing both high- and low-affinity sites for reserpine and (b) an inactive form with only the low-affinity R2 sites.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6708929

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  34 in total

1.  Homology of a vesicular amine transporter to a gene conferring resistance to 1-methyl-4-phenylpyridinium.

Authors:  Y Stern-Bach; J N Keen; M Bejerano; S Steiner-Mordoch; M Wallach; J B Findlay; S Schuldiner
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

2.  Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2.

Authors:  Justin R Nickell; Guangrong Zheng; Agripina G Deaciuc; Peter A Crooks; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2010-09-28       Impact factor: 4.030

Review 3.  Proton-dependent multidrug efflux systems.

Authors:  I T Paulsen; M H Brown; R A Skurray
Journal:  Microbiol Rev       Date:  1996-12

4.  Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators.

Authors:  Samuel Frank
Journal:  BMC Neurol       Date:  2009-12-18       Impact factor: 2.474

5.  Emulating proton-induced conformational changes in the vesicular monoamine transporter VMAT2 by mutagenesis.

Authors:  Dana Yaffe; Ariela Vergara-Jaque; Lucy R Forrest; Shimon Schuldiner
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-07       Impact factor: 11.205

Review 6.  Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse.

Authors:  Peter A Crooks; Guangrong Zheng; Ashish P Vartak; John P Culver; Fang Zheng; David B Horton; Linda P Dwoskin
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

7.  High-efficiency expression and characterization of the synaptic-vesicle monoamine transporter from baculovirus-infected insect cells.

Authors:  M K Sievert; D S Thiriot; R H Edwards; A E Ruoho
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

8.  Directed evolution reveals hidden properties of VMAT, a neurotransmitter transporter.

Authors:  Yael Gros; Shimon Schuldiner
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

Review 9.  Treatment of Huntington's disease.

Authors:  Samuel Frank
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

10.  Interactions of methylenedioxymethamphetamine with monoamine transmitter release mechanisms in rat brain slices.

Authors:  J L Fitzgerald; J J Reid
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-03       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.